Brain tumors are the leading cause of cancer-related death in children. Experimental in vitro models that faithfully capture the hallmarks and tumor heterogeneity of pediatric brain cancers are limited and hard to establish. We present a protocol that enables efficient generation, expansion, and biobanking of pediatric brain cancer organoids. Utilizing our protocol, we have established patient-derived organoids (PDOs) from ependymomas, medulloblastomas, low-grade glial tumors, and patient-derived xenograft organoids (PDXOs) from medulloblastoma xenografts. PDOs and PDXOs recapitulate histological features, DNA methylation profiles, and intratumor heterogeneity of the tumors from which they were derived. We also showed that PDOs can be xenografted. Most interestingly, when subjected to the same routinely applied therapeutic regimens, PDOs respond similarly to the patients. Taken together, our study highlights the potential of PDOs and PDXOs for research and translational applications for personalized medicine.
Patient- and xenograft-derived organoids recapitulate pediatric brain tumor features and patient treatments / Lago, Chiara; Federico, Aniello; Leva, Gloria; Mack, Norman L; Schwalm, Benjamin; Ballabio, Claudio; Gianesello, Matteo; Abballe, Luana; Giovannoni, Isabella; Reddel, Sofia; Rossi, Sabrina; Leone, Nicolas; Carai, Andrea; Mastronuzzi, Angela; Bisio, Alessandra; Soldano, Alessia; Quintarelli, Concetta; Locatelli, Franco; Kool, Marcel; Miele, Evelina; Tiberi, Luca. - In: EMBO MOLECULAR MEDICINE. - ISSN 1757-4676. - 15:12(2023), pp. 1-28. [10.15252/emmm.202318199]
Patient- and xenograft-derived organoids recapitulate pediatric brain tumor features and patient treatments
Soldano, Alessia;
2023-01-01
Abstract
Brain tumors are the leading cause of cancer-related death in children. Experimental in vitro models that faithfully capture the hallmarks and tumor heterogeneity of pediatric brain cancers are limited and hard to establish. We present a protocol that enables efficient generation, expansion, and biobanking of pediatric brain cancer organoids. Utilizing our protocol, we have established patient-derived organoids (PDOs) from ependymomas, medulloblastomas, low-grade glial tumors, and patient-derived xenograft organoids (PDXOs) from medulloblastoma xenografts. PDOs and PDXOs recapitulate histological features, DNA methylation profiles, and intratumor heterogeneity of the tumors from which they were derived. We also showed that PDOs can be xenografted. Most interestingly, when subjected to the same routinely applied therapeutic regimens, PDOs respond similarly to the patients. Taken together, our study highlights the potential of PDOs and PDXOs for research and translational applications for personalized medicine.File | Dimensione | Formato | |
---|---|---|---|
Patient-+and+xenograft-derived+organoids+recapitulate+pediatric+brain+tumor+features+and+patient+treatments+_compressed.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
549.25 kB
Formato
Adobe PDF
|
549.25 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.